<DOC>
	<DOCNO>NCT01570049</DOCNO>
	<brief_summary>The purpose study determine whether bendamustine HCl injection safe effective treatment Rituximab refractory relapse B-cell indolent lymphoma .</brief_summary>
	<brief_title>Safety Efficacy Study Bendamustine Treat Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>This multicenter , open label study evaluate safety efficacy bendamustine HCl patient indolent Non-hodgkin 's lymphoma relapse rituximab treatment . This injection give i.v . infusion &gt; = 60 minute day 1 2 every 21-day treatment cycle . Patients treat 8 cycle unless progressive disease unacceptable toxicity take place . Patients follow 1 year evaluate progression free survival ( PFS ) overall survival ( OS ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>18 75 year Bcell indolent lymphoma prove biopsy , exclude CLL/SLL Rituximab refractory relapse lymphoma patient At least 1 measurable tumor short diameter &gt; 1.0cm long diameter &gt; 1.5cm ECOG PS ≤ 2 Anticipated Survival 3 month Hematopoietic function normal 14 day enrollment ( unless abnormities relate lymphoma aggression ) , include : hemoglobin ( Hb ) ≥ 8.0g/dl ( 5.0mmol/L ) ; absolute neutrophil count ( ANC ) ≥ 1.5X109/L ; Platelet count ( PLT ) ≥ 80X109/L . Acceptable range abnormities relate lymphoma aggression : Platelet count ( PLT ) ≥ 50X109/L ; White blood cell count ( WBC ) ≥ 3.5X109/L ; Absolute neutrophil count ( ANC ) ≥ 1.0X109/L Female subject pregnant breastfeed , contraceptive method clinical trial 12 month thereafter . Subject ( his/her legal representative ) agree participate trial sign inform consent form Those tolerate bendamustine treatment accord investigator view Transferred high grade malignant lymphoma ( low grade follicular lymphoma ) 3b grade follicular lymphoma With central nervous system diseases medical history ( e.g. , central nervous system lymphoma lymphoma related meningitis ) With anticancer treatment last 4 week Regularly administrate corticosteroid last 4 week , unless dose less equivalent 20mg/d prednisone Had tumor tumor , include nonmelanoma skin cancer cervical carcinoma situ treat properly Underwent surgical operation within 28 day enrollment ( exclude lymph node biopsy ) Renal disfunction : serum creatinine 1.5 time upper limit normal value Hepatic insufficiency : serum total bilirubin &gt; 1.5 time upper limit normal value ; AST , ALT &gt; 2.5 time upper limit normal value Known HIV infection HBV , HCV relate active infection ; HBsAg positive ; HBcAb positive virus copy number &gt; 1000 For patient severe medical disease interfere participation study ( e.g. , infection diabetes control well , gastric ulcer , lung disease , active autoimmune disease ) , suitability participation judge investigator Patients participate clinical study get medical treatment within 30 day prior enrollment trial Other medical psychological condition influence patient participation signing informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Single arm</keyword>
	<keyword>Open label</keyword>
	<keyword>Bendamustine HCl</keyword>
	<keyword>Non-hodgkin 's lymphoma</keyword>
</DOC>